药品注册申请号:018608
申请类型:NDA (新药申请)
申请人:HOSPIRA
申请人全名:HOSPIRA INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 PLEGISOL IN PLASTIC CONTAINER CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SOLUTION;PERFUSION, CARDIAC 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML Yes Yes AT 1982/02/26 1982/02/26 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2002/12/16 SUPPL-31(补充) Approval Labeling STANDARD
2000/12/12 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
1999/10/18 SUPPL-34(补充) Approval Labeling STANDARD
1997/11/14 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
1997/09/05 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
1997/03/20 SUPPL-30(补充) Approval Manufacturing (CMC) PRIORITY
1997/03/20 SUPPL-29(补充) Approval Manufacturing (CMC) PRIORITY
1992/01/28 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
1991/09/10 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
1990/02/22 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1990/01/11 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1989/09/13 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1987/03/09 SUPPL-10(补充) Approval Labeling
1987/03/09 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1986/11/26 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
1986/08/08 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1986/01/31 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1986/01/31 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1985/10/29 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1985/09/26 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
1984/11/09 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
1984/10/22 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1984/10/17 SUPPL-8(补充) Approval Manufacturing (CMC) PRIORITY
1984/03/21 SUPPL-7(补充) Approval Manufacturing (CMC) PRIORITY
1984/03/01 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
1982/10/21 SUPPL-1(补充) Approval Labeling
1982/07/26 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1982/06/18 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1982/02/26 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE 剂型/给药途径:SOLUTION;PERFUSION, CARDIAC 规格:17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML 治疗等效代码:AT
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
018608 001 NDA PLEGISOL IN PLASTIC CONTAINER CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SOLUTION;PERFUSION, CARDIAC 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML Prescription Yes Yes AT 1982/02/26 HOSPIRA
075323 001 ANDA CARDIOPLEGIC IN PLASTIC CONTAINER CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SOLUTION;PERFUSION, CARDIAC 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML Prescription No No AT 2000/04/21 BAXTER HLTHCARE
214623 001 ANDA CARDIOPLEGIC IN PLASTIC CONTAINER CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE SOLUTION;PERFUSION, CARDIAC 17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML Prescription No No AT 2022/02/18 FRESENIUS KABI USA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database